His research interests are persued as the coordinator of the Cancer Genetic Group of CI-IPOP, which aims to characterize the pattern of germline and somatic genetic alterations that are involved in carcinogenesis, under the assumption that tailor-made therapy specifically directed towards the altered metabolism of tumor cells requires exact knowledge about the inherited and acquired genomic abnormalities of individual patients, not just about diagnostic categories. Over the years his group has discovered several novel gene fusions in different malignant diseases, as well as several founder germline variants associated with cancer predisposition. As PI or Co-PI, he has raised competitive funding at national and European level. He has authored or co-authored more than 300 publications in international peer-reviewed journals and several book chapters and his publications were cited more than 11.000 times (H-index: 55).